OTCMKTS:IMMVF Immunovia AB (publ) (IMMVF) Stock Price, News & Analysis → If you have $2,500 bucks… check this out (From DTI) (Ad) Free IMMVF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.15▼$0.1550-Day Range N/A52-Week Range$0.84▼$2.00VolumeN/AAverage Volume12,942 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisShort InterestStock AnalysisShort Interest Get Immunovia AB (publ) alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Immunovia AB (publ) Stock (OTCMKTS:IMMVF)Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.Read More Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << IMMVF Stock News HeadlinesMarch 17, 2023 | prnewswire.comImmunovia publishes prospectus relating to the rights issueDecember 5, 2022 | finance.yahoo.comImmunovia strengthens US organization to continue commercialization of its novel IMMray™ PanCan-d testApril 29, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. November 30, 2022 | finance.yahoo.comCenters for Medicare & Medicaid Services finalizes its payment determination and sets a rate of $897 for Immunovia's IMMray PanCan-d testNovember 16, 2022 | finance.yahoo.comChief Executive Offier, Philipp Mathieu, buys Immunovia warrantsNovember 12, 2022 | finance.yahoo.comImmunovia announces the financial calendar for financial year 2023November 10, 2022 | finance.yahoo.comImmunovia Publishes Interim Report Jan-Sep 2022November 5, 2022 | finanznachrichten.deImmunovia AB: Invitation to Immunovia's Q3 presentationApril 29, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! November 3, 2022 | finance.yahoo.comInvitation to Immunovia's Q3 presentationOctober 20, 2022 | finance.yahoo.comNomination Committee appointed for the 2023 Annual General Meeting of Immunovia AB (Publ)October 19, 2022 | finance.yahoo.comImmunovia announces executive management team changes to accelerate execution of strategic prioritiesOctober 18, 2022 | finanznachrichten.deImmunovia AB: Immunovia launches a strategic partnership with Proteomedix to leverage R&D efforts with increased focus on commercializationOctober 17, 2022 | finance.yahoo.comImmunovia launches a strategic partnership with Proteomedix to leverage R&D efforts with increased focus on commercializationSeptember 29, 2022 | investing.comAttendo International publ AB (ATTE)September 26, 2022 | finance.yahoo.comCenters for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia's IMMray PanCan-d testSeptember 9, 2022 | investing.comImmunovia publ AB (IMMNOV)August 25, 2022 | finanznachrichten.deImmunovia AB: Immunovia Publishes Interim Report Jan-June 2022August 24, 2022 | finance.yahoo.comImmunovia Publishes Interim Report Jan-June 2022August 23, 2022 | finance.yahoo.comImmunovia to present at Gilmartin Group's Emerging Growth Company ShowcaseAugust 22, 2022 | finance.yahoo.comInvitation to Immunovia's Q2 presentationAugust 11, 2022 | finance.yahoo.comImmunovia, Inc. Issued Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray™ PanCan-d testJuly 5, 2022 | finance.yahoo.comImmunovia: CPT PLA Code for the IMMray™ PanCan-d test approvedJune 30, 2022 | finance.yahoo.comThe PanDIA-1 study, for early detection of pancreatic cancer in newly onset type 2 diabetics, moves into next phaseJune 27, 2022 | finance.yahoo.comPanFAM-1 Results Partly InconclusiveJune 27, 2022 | finance.yahoo.comInvitation to Immunovia's Presentation of PanFAM-1 ResultsJune 3, 2022 | seekingalpha.comImmunovia AB appoints Philipp Mathieu as permanent CEOSee More Headlines Receive IMMVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovia AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/29/2013Today4/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IMMVF CUSIPN/A CIKN/A Webwww.imvaccine.com Phone(902) 492-1819FaxN/AEmployees69Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Patrik DahlenChief Exec. OfficerMr. Hans Liljenborg (Age 63)Chief Financial Officer Ms. Lotta Blomgren (Age 61)Operations Director Mr. Rolf Ehrnström (Age 68)Chief Scientific Officer Ms. Laura Chirica (Age 53)Chief Commercial Officer Mr. Henrik Winther (Age 55)Sr. VP of Bus. Devel. Mr. Michael PettigrewSr. VP of Sales - North AmericaMs. Linda Dexlin Mellby (Age 42)VP of R&D Dr. Thomas C. King (Age 63)Medical Director More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors IMMVF Stock Analysis - Frequently Asked Questions Are investors shorting Immunovia AB (publ)? Immunovia AB (publ) saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 14,800 shares, a drop of 9.2% from the February 29th total of 16,300 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days. View Immunovia AB (publ)'s Short Interest. How were Immunovia AB (publ)'s earnings last quarter? Immunovia AB (publ) (OTCMKTS:IMMVF) announced its quarterly earnings results on Friday, November, 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. This page (OTCMKTS:IMMVF) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupTrump is sounding the alarmPreserve GoldHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovia AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
